Embed presentation
Downloaded 41 times























This document discusses moving beyond the traditional Framingham Risk Score for assessing individual coronary heart disease risk. It outlines three areas showing promise: (1) biomarkers like hsCRP and LpPLA2 that can identify pre-clinical disease, (2) vascular imaging like CIMT and CACS that provide more direct measures of atherosclerosis, and (3) genomics though the effects of common gene variants on risk are small and replication has been difficult. Biomarkers and imaging allow refining risk assessment, especially for those at intermediate Framingham risk, while challenges remain in applying genetics to individual risk prediction.





















